|Bid||0.25 x 0|
|Ask||0.27 x 0|
|Day's Range||0.2500 - 0.2550|
|52 Week Range||0.2000 - 0.6000|
|Beta (3Y Monthly)||0.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.26|
MELBOURNE, Australia, Jan. 08, 2019 -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and.
If you own shares in Immuron Limited (ASX:IMC) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive Officer. Dr Jacob is the former Chairman, President and Chief Executive Officer of Synergy Pharmaceuticals Inc. a Nasdaq-listed public biopharmaceutical company located in New York, NY focused on the development of drugs to treat gastrointestinal disorders and diseases.
Australian Travelan® sales continue to grow, with a Q1 CY19 figure of $340K AUD. Global Immuron Limited sales for Q1 2019 reached $482K AUD which is a 2% increase on the same quarter of last financial year. NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today announced that the IMM-124E NASH clinical study findings will be presented by Professor Arun Sanyal at the American Association for the study of Liver Disease which will be held in San Francisco, California during the 9th – 13th of November 2018.
If you want to know who really controls Immuron Limited (ASX:IMC), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...